Scotia Capital’s Pfizer PFE Stock Holding History

Scotia Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.7M	Sell	1,058,826 -41,315	-4%	-$1.1M	0.12%	104
2025 Q4	$27.4M	Buy	1,100,141 +142,657	+15%	+$3.6M	0.11%	108
2025 Q3	$24.4M	Buy	957,484 +168,921	+21%	+$4.17M	0.1%	113
2025 Q2	$19.1M	Buy	788,563 +18,981	+2%	+$443K	0.09%	131
2025 Q1	$19.5M	Sell	769,582 -24,664	-3%	-$645K	0.1%	121
2024 Q4	$21.1M	Sell	794,246 -328,203	-29%	-$8.9M	0.11%	110
2024 Q3	$32.5M	Buy	1,122,449 +45,081	+4%	+$1.32M	0.17%	85
2024 Q2	$30.1M	Buy	1,077,368 +19,886	+2%	+$547K	0.18%	86
2024 Q1	$29.3M	Sell	1,057,482 -206,262	-16%	-$5.72M	0.17%	85
2023 Q4	$36.4M	Sell	1,263,744 -365,560	-22%	-$11.1M	0.23%	70
2023 Q3	$54M	Sell	1,629,304 -316,862	-16%	-$11.2M	0.39%	51
2023 Q2	$71.4M	Sell	1,946,166 -51,509	-3%	-$2M	0.49%	41
2023 Q1	$81.5M	Buy	1,997,675 +3,489	+0.2%	+$151K	0.6%	38
2022 Q4	$102M	Sell	1,994,186 -13,791	-0.7%	-$661K	0.79%	33
2022 Q3	$87.9M	Sell	2,007,977 -91,256	-4%	-$4.43M	0.71%	36
2022 Q2	$110M	Sell	2,099,233 -64,046	-3%	-$3.26M	0.82%	31
2022 Q1	$112M	Buy	2,163,279 +22,925	+1%	+$1.19M	0.71%	35
2021 Q4	$126M	Sell	2,140,354 -32,696	-2%	-$1.62M	0.83%	32
2021 Q3	$93.5M	Sell	2,173,050 -335,973	-13%	-$14.9M	0.68%	35
2021 Q2	$98.3M	Buy	2,509,023 +221,386	+10%	+$8.61M	0.72%	35
2021 Q1	$82.9M	Buy	2,287,637 +17,140	+0.8%	+$609K	0.67%	38
2020 Q4	$83.6M	Buy	2,270,497 +99,400	+5%	+$3.65M	0.77%	32
2020 Q3	$75.6M	Buy	2,171,097 +130,003	+6%	+$4.56M	0.82%	32
2020 Q2	$63.5M	Buy	2,041,094 +16,989	+0.8%	+$577K	0.89%	30
2020 Q1	$62.7M	Buy	2,024,105 +110,350	+6%	+$3.76M	0.87%	31
2019 Q4	$71.2M	Buy	1,913,755 +150,327	+9%	+$5.35M	0.79%	31
2019 Q3	$60.1M	Buy	1,763,428 +145,373	+9%	+$5.29M	0.71%	36
2019 Q2	$66.5M	Buy	1,618,055 +228,704	+16%	+$9.08M	0.81%	30
2019 Q1	$56M	Buy	1,389,351 +54,010	+4%	+$2.16M	0.72%	34
2018 Q4	$55.3M	Buy	1,335,341 +124,273	+10%	+$5.16M	0.82%	31
2018 Q3	$50.6M	Sell	1,211,068 -122,294	-9%	-$4.71M	0.64%	38
2018 Q2	$44.6M	Buy	1,333,362 +16,769	+1%	+$573K	0.62%	38
2018 Q1	$44.3M	Buy	1,316,593 +3,762	+0.3%	+$129K	0.61%	38
2017 Q4	$45.1M	Buy	1,312,831 +29,843	+2%	+$1.02M	0.6%	39
2017 Q3	$43.4M	Buy	1,282,988 +244,209	+24%	+$7.85M	0.62%	38
2017 Q2	$33.1M	Buy	1,038,779 +84,925	+9%	+$2.68M	0.56%	40
2017 Q1	$31M	Sell	953,854 -70,670	-7%	-$2.23M	0.53%	43
2016 Q4	$31.6M	Buy	1,024,524 +42,904	+4%	+$1.31M	0.5%	41
2016 Q3	$31.5M	Buy	981,620 +54,526	+6%	+$1.82M	0.58%	34
2016 Q2	$31M	Buy	927,094 +94,398	+11%	+$3.01M	0.63%	32
2016 Q1	$23.4M	Buy	832,696 +74,018	+10%	+$2.11M	0.51%	44
2015 Q4	$22.4M	Buy	758,678 +21,863	+3%	+$688K	0.51%	41
2015 Q3	$22M	Buy	736,815 +75,786	+11%	+$2.43M	0.5%	39
2015 Q2	$21M	Sell	661,029 -79,638	-11%	-$2.6M	0.42%	48
2015 Q1	$24.5M	Buy	740,667 +33,643	+5%	+$1.07M	0.63%	35
2014 Q4	$20.9M	Buy	707,024 +45,420	+7%	+$1.3M	0.55%	40
2014 Q3	$18.5M	Sell	661,604 -28,934	-4%	-$812K	0.4%	47
2014 Q2	$19.5M	Buy	690,538 +52,294	+8%	+$1.49M	0.42%	48
2014 Q1	$19.4M	Buy	638,244 +68,999	+12%	+$2.06M	0.43%	48
2013 Q4	$16.5M	Buy	569,245 +65,251	+13%	+$1.9M	0.39%	47
2013 Q3	$13.7M	Buy	503,994 +65,051	+15%	+$1.77M	0.37%	52
2013 Q2	$11.6M	Buy	+438,943	New	+$12.1M	0.45%	50

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Scotia Capital's PFE Position: Q1 2026 in Review

Scotia Capital reduced its Pfizer (PFE) stake by 3.8% in Q1 2026, selling an estimated $1.1M and leaving 1,058,826 shares worth $29.7M. The position accounts for 0.12% of the portfolio, ranked #104.

Scotia Capital first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $126M in Q4 2021. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Scotia Capital held 1,058,826 shares of Pfizer worth $29.7M as of Q1 2026.
Scotia Capital sold 41,315 Pfizer shares in Q1 2026, an estimated $1.1M.
Pfizer made up 0.12% of Scotia Capital's portfolio in Q1 2026, its #104 holding.
Scotia Capital first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
Scotia Capital's Pfizer position peaked at $126M in Q4 2021.
2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.